Abstract 5668
Background
Concordance between whole genome sequencing (WGS)/whole exome sequencing (WES) and circulating tumor DNA (ctDNA) is not known. Therefore, we studied concordance between matched WGS/WES and ctDNA in various solid tumors. In addition, we carried out an analysis of hotspot and actionable alterations in our data.
Methods
Retrospective analysis of 64 stage III/IV solid tumors (Gastrointestinal n = 20 Breast n = 12 Lung n = 19 Other n = 13) who underwent matched WGS/WES and ctDNA (77 genes) by commercially available platforms. Concordance was determined at patient and gene levels.
Results
Patient concordance between tissue and ctDNA results was 58% (n = 37). Concordance was higher when patients received systemic chemotherapy prior to tissue NGS and ctDNA compared to no chemotherapy (78% n = 21 Vs 43% n = 12, respectively p = 0.01) and positively correlated increasing tumor mutation burden. There was no significant difference in concordance when time interval between tissue NGS and ctDNA analysis was evaluated (55% n = 24 Vs 65% n = 13, <90 days Vs > =90 days respectively p = 0.20). Similarly, no statistical difference in concordance was found when tissue NGS was done on primary or metastatic sites (48% n = 12 Vs 64% n = 25, respectively p = 0.20). TMB positively correlated with the number of ctDNA mutations only in those who received chemotherapy (r(25)=0.74 p < 0.0001) but did not correlate in chemotherapy naïve (r(27)=0.11 p = 0.60). Gene level concordance between tissue and ctDNA was 21% across all tumor types. The most common concordant genes with somatic alterations across all tumors were TP53, KRAS, and PIK3CA. 121 hotspots were identified in tumor NGS and 63 were in ctDNA. Hotspot concordance was 34%. Tissue NGS identified 68 targetable alterations in 31 patients and ctDNA analysis identified 87 in 34 patients. 48 of these were concordant and 59 were discordant (tissue 20, ctDNA 39).
Conclusions
Our analysis noted significant discordance between WGS/WES and ctDNA analysis. TMB and prior chemotherapy may affect concordance between NGS and ctDNA. Tissue NGS and ctDNA are complementary modalities and incorporating ctDNA with tissue NGS can increase the likelihood of capturing additional targetable alterations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract
4094 - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate
Presenter: Marília Silva
Session: Poster Display session 1
Resources:
Abstract